Replimune Corp - REPL Net earnings per share for the last four quarters

Official company branding of Replimune Corp (REPL)

Serving as a valuation tool, the EPS TTM chart on the GURU.Markets platform, where the value is 18.80, highlights the potential of Replimune Group, Inc. (REPL) to establish strict pricing power due to price-insensitive demand. The current resilience of the business depends on the rate of capital expenditure prior to the start of sales, despite the success of clinical trials. The company creates unique viruses that transform neoplasms into their own vaccines for their destruction.

Replimune (REPL) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/14/2026

REPL (Replimune Corp): analytical breakdowns and indicator data

- current price and projected stock value:
Price Performance Chart replimune.com|REPL - Analyst Consensus Forecast
- issuer market value details:
Market Capitalization Replimune Group Inc|REPL - Total Company Value
- book value of equity indicators:
Accounting Value per Share Replimune|REPL - Company Book Value|Market Cap to Net Assets Ratio replimune.com|REPL - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital Replimune Group, Inc.|REPL - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Replimune Inc.|REPL - Company Debts|Debts to Book Value Replimune Group Inc|REPL - Company Long-Term Liabilities|Short-Term Indebtedness Replimune|Intermediate Liquidity Ratio replimune.com
- earnings and market multiples details:
REPL - Net Profit|Expected Net Income Replimune Group, Inc.|REPL - P/E Multiple|Projected Price to Earnings Ratio Replimune Group Inc|REPL - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Replimune Group Inc|REPL - Operating profit EBITDA|Net earnings per share (EPS TTM) Replimune|REPL - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months replimune.com|REPL - Net earnings per share growth this year|Expected net earnings per share growth next year Replimune Group, Inc.
- revenue and sales details:
REPL - Company Revenue|Company Future Revenue replimune.com|REPL - P/S Multiple|Market Cap to Future Revenue Ratio Replimune Group Inc
Initial company analysis:REPL, replimune.com
Mass-produced product of replimune.com

Year-over-year (TTM) EPS growth measures the net profit per share dynamics over the last twelve months. While an acceleration of this metric reduces fundamental risks, it may lead to an overvaluation of the stock's market price. By analyzing the percentage change trend of EPS YoY TTM, an investor sees the current value of 18.80. This metric reflects the business scaling efficiency of Replimune Group, Inc. (REPL) amid the modernization of laboratories for the production of therapeutic vaccines.

Direct competitors

Earnings per share for the trailing year IBRX (immunitybio.com)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Arcus Bio|Net earnings per share for the last 12 months Zymeworks Biopharmaceuticals (ZYME)|Earnings per share for the last twelve months Tango Therapeutics (TNGX)|Net earnings per share for the last 12 months iovance.com IOVA|Immatics - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc XNCR|CMPX - Earnings per share for the last twelve months|LYEL (Lyell Pharma) - Earnings per share for the last 12 months|Innate Pharma S.A. (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics, Inc.)|Earnings per share for the trailing year IMMX|ALX Oncology Holdings - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months cuebiopharma.com|pdsbiotech.com (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings - Earnings per share for the trailing year|MAIA (MAIA Biotechnology) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) liminatuspharma.com|Earnings per share for the last twelve months LAVA Therapeutics N.V. (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Therapeutics Inc (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Earnings per share for the trailing year TOVX (therivabio.com)|GRTS: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Kineta Inc (KA)|Earnings per share for the last twelve months NexImmune Corp|Turnstone Biologics Corporation - Earnings per one share for the last 12 months|Earnings per share for the last twelve months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months HARP (harpoontx.com)